Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Shares Down 5.3% – Time to Sell?

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP)’s stock price fell 5.3% during mid-day trading on Thursday . The company traded as low as $4.79 and last traded at $4.83. Approximately 249,718 shares traded hands during mid-day trading, an increase of 31% from the average daily volume of 190,897 shares. The stock had previously closed at $5.10.

Analyst Upgrades and Downgrades

Separately, Zacks Research upgraded Armata Pharmaceuticals to a “hold” rating in a research report on Monday, May 18th. Two investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $15.00.

Armata Pharmaceuticals Stock Performance

The firm’s 50 day moving average price is $7.45 and its two-hundred day moving average price is $8.41. The company has a market cap of $156.38 million, a P/E ratio of -0.55 and a beta of 1.26.

Armata Pharmaceuticals (NYSEAMERICAN:ARMP) last issued its earnings results on Wednesday, May 13th. The company reported ($3.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($2.78). The company had revenue of $0.79 million for the quarter, compared to analyst estimates of $0.74 million. As a group, analysts forecast that Armata Pharmaceuticals, Inc. will post -1.88 EPS for the current fiscal year.

Institutional Trading of Armata Pharmaceuticals

Several large investors have recently made changes to their positions in the company. Bank of America Corp DE increased its position in Armata Pharmaceuticals by 233.2% in the 1st quarter. Bank of America Corp DE now owns 11,714 shares of the company’s stock valued at $120,000 after buying an additional 8,198 shares in the last quarter. Sei Investments Co. bought a new position in Armata Pharmaceuticals in the first quarter worth approximately $760,000. Madison Asset Management LLC acquired a new stake in Armata Pharmaceuticals in the first quarter valued at approximately $21,583,000. Millennium Management LLC acquired a new stake in Armata Pharmaceuticals in the fourth quarter valued at approximately $164,000. Finally, 683 Capital Management LLC bought a new stake in shares of Armata Pharmaceuticals during the fourth quarter valued at approximately $878,000. 3.57% of the stock is currently owned by institutional investors and hedge funds.

Armata Pharmaceuticals Company Profile

Armata Pharmaceuticals, Inc is a clinical-stage biotechnology company developing targeted bacteriophage therapies to address antibiotic-resistant bacterial infections. The company’s proprietary platform harnesses naturally occurring viruses that selectively infect and destroy bacterial pathogens, offering a novel approach to combating drug-resistant strains that pose significant challenges in hospital and community settings.

Armata’s pipeline includes phage-based candidates aimed at Pseudomonas aeruginosa, a common cause of hospital-acquired pneumonia and infections in cystic fibrosis patients, as well as Staphylococcus aureus and other priority pathogens.